Beam Therapeutics (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, reported fourth-quarter and full-year 2025 financial results on February 24, 2026.
As of December 31, 2025, Beam ended the year with $1.25 billion in cash, cash equivalents and marketable securities.
The company secured a $500 million senior secured credit facility with Sixth Street, of which it expects to draw a minimum of $200 million.
The financing provides extended runway to support ongoing clinical development and potential commercialization efforts.
Beam introduced BEAM-304, a new in vivo base editing program designed to correct the most common mutations underlying phenylketonuria (PKU), a rare genetic disorder that can lead to severe neurological impairment if untreated.
The company anticipates filing an investigational new drug application (IND) for BEAM-304 in 2026.
The company also reiterated its expectation for a potential Biologics License Application (BLA) submission for BEAM-101 (ristosertib-cel), its ex vivo base-edited autologous cell therapy candidate for sickle cell disease, as early as year-end 2026.
Beam also plans to outline next steps for the pivotal development path of BEAM-302, its in vivo base editing program for alpha-1 antitrypsin deficiency, in the first quarter of 2026.